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Partial monosomy14q involving FOXG1 and
NOVA1 in an infant with microcephaly,
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Abstract
Background: FOXG1 gene mutations have been associated with the congenital variant of Rett syndrome (RTT) since
the initial description of two patients in 2008. The on-going accumulation of clinical data suggests that the FOXG1-
variant of RTT forms a distinguishable phenotype, consisting mainly of postnatal microcephaly, seizures, hypotonia,
developmental delay and corpus callosum agenesis.
Case presentation: We report a 6-month-old female infant, born at 38 weeks of gestation after in vitro fertilization,
who presented with feeding difficulties, irritability and developmental delay from the first months of life. Microcephaly
with bitemporal narrowing, dyspraxia, poor eye contact and strabismus were also noted. At 10 months, the proband
exhibited focal seizures and required valproic acid treatment. Array-Comparative Genomic Hybridization revealed a 4.
09 Mb deletion in 14q12 region, encompassing the FOXG1 and NOVA1 genes. The proband presented similar feature
with patients with 14q12 deletions except for dysgenesis of corpus callosum. Disruption of the NOVA1 gene which
promotes the motor neurons apoptosis has not yet been linked to any human phenotypes and it is uncertain if it
affects our patient’s phenotype.
Conclusions: Since our patient is the first reported case with deletion of both genes (FOXG1-NOVA1), thorough clinical
follow up would further delineate the Congenital Rett-Variant phenotypes.
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Background
Since 2008, when mutations in the FOXG1 gene were ini-
tially described in two patients with Rett-like symptoms,
more than 90 patients have been reported to have muta-
tions involving the FOXG1 gene [1–6]. Rett syndrome is
typically an X-linked neurodegenerative condition [6] that
was initially described by Andreas Rett in 1966. Common
clinical features of Rett syndrome include postnatal micro-
cephaly, autism, seizures, breathing abnormalities, growth
retardation and gait apraxia [7, 8]. The majority of patients
with typical Rett syndrome carry mutations in the gene en-
coding Methyl-CpG-binding protein 2 (MECP2) located at
Xq28. Variant forms of Rett syndrome have been revised
in 2010 by Neul et al [7]. He classified them in to three
main variant categories: 1. Preserved speech, 2. early sei-
zures and, 3. the congenital variant. Mutations in the
cyclin-dependent kinase-like 5 (CDKL5) gene located in
Xp22 are found in most cases of early-onset seizure vari-
ants, while the congenital variant of the syndrome has re-
cently been found to be associated with heterozygous
mutations or deletions in the forkhead box protein G1
(FOXG1) gene, located in the 14q12 chromosomal region
[7, 9–11]. In this study, we report a new case of atypical
Rett Syndrome with a 14q12 deletion, 4.09 Mb in size,
encompassing only two genes, the FOXG1 and the NOVA1
and we discuss the role of the NOVA1 haploinsufficiency.
Case presentation
Our patient was a 6-month- old female infant and the
only child of non-consanguineous parents. She was born
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by caesarean section at 38 weeks of gestation. Her birth
weight was 2.990 gr (25th -50th centile), her length was
49 cm (25th -50th centile) and her head circumference
was 33 cm (10–25th centile).
It should be noted that the embryo was the product of
in vitro fertilization (IVF) by intracytoplasmic sperm in-
jection (ICSI) due to the husband’s low sperm count.
The mother underwent treatment with Follitropin Beta
(Puregon), human Chorionic Gonadotropin, hCG (Preg-
nyl), and Cetrorelix Acetate (Cetrotide).
The patient as a neonate was hypotonic. She was re-
ferred for clinical evaluation at the age of 6 months due
to irritability and feeding difficulties. The examinations
revealed peripheral hypertonia, psychomotor retardation
(limited facial expression—no smile, poor eye contact),
borderline microcephaly (head circumference of 39 cm,
at 3rd centile) (Fig. 1a), periodical stereotypic movements
and minor dysmorphic features such as a small forehead
with bitemporal narrowing, strabismus, broad base to
nose and long philtrum. Her weight was 6.18 kg (25th
centile) and her height was 62 cm (25th centile).
Due to gastroesophageal reflux she was treated with
ranitidine.
Haematological, biochemical, metabolic, thyroid, am-
monia and blood gasses were all normal. The ultra-
sounds of the heart and abdomen were also normal.
At 10 months the proband exhibited focal seizures and
required valproic acid treatment. Sleep deprived EEG
examination revealed slower focal activity for her age
and sleep spindles which are indicative signs of focal
cerebral dysfunction. Brain magnetic resonance imaging
(MRI) showed no serious findings except for a septum
pellucidum cyst and brain asymmetry—the left hemi-
sphere was larger than the right one.
At the age of 12 months, the head circumference was
40.7 cm (<< 3rd centile) (Fig. 1a) while the height and
Fig. 1 Growth curve ¨Head circumference—for—age GIRLS. First Paediatric department, National and Kapodistrian University of Athens. Professor
G.Chroussos. The standard curves are used by the Greek National Health System
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weight remained between 10th and 25th centile. Severe
neurodevelopmental delay was obvious.
Re-examination at the age of 19- months and 2-
years, revealed head circumference of 42 cm (<< 3rd
centile) (Fig. 1a), height of 75.5 cm (slightly below the
3rd centile) and weight of 9 Kg (slightly below the 3rd
centile). The proband exhibited severe psychomotor
retardation as she could neither sit independently nor
speak at all.
Chromosome and array-based analysis
Metaphase chromosomes were obtained from phyto-
hemagglutinin (PHA)-stimulated peripheral blood
lymphocytes and high resolution (550–650 bands) thy-
midine treatment G-banding karyotype analysis was
performed, using standard procedures. Twenty meta-
phase spreads were analysed, and the result was a nor-
mal female karyotype (46, XX). The molecular analysis
of the MECP2 gene was normal also.
Fig. 2 Array-CGH analysis detected a 4.09 Mb loss of the copy numbers in the spanning region 14q12. b Chromosome 14, region 25,843,560-29,938,629.
Represents the 4,095,070 bp deletion described in our case report. The region includes both FOXG1 and NOVA1 genes. Figure adapted from
http://genome.ucsc.edu/ Accessed at 18/10/2015
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Further investigation with array-Comparative Genomic
Hybridization was performed by hybridizing the sample
against a male human reference commercial DNA sam-
ple (Promega biotech) using an array-CGH platform that
includes 60,000 oligonucleotides distributed across the
entire genome (Agilent Technologies). The statistical
test used as parameter to estimate the number of copies
was ADAM-2 (provided by the DNA analytics software,
Agilent Techn.) with a window of 0.5 Mb, A = 6. Only
those copy number changes that affect at least 5 consecu-
tive probes with identically oriented change were consid-
ered as Copy Number Variations (CNV). For the majority
of the genome, the average genomic power of resolution
of this analysis was 200 kilobases. Array-CGH analysis
detected a 4.09 Mb loss in the 14q12 region (Fig. 2a).
The deleted segment was mapped at chr14:25,843,560-
29,938,629 region. The genomic coordinates are listed
according to genomic build GRCh37/hg19, and in-
cludes FOXG1 and NOVA1 genes (Fig. 2b).
The result of array-CGH was confirmed with FISH.
Ten metaphases were analysed from phytohemagglutinin
(PHA)-stimulated peripheral blood lymphocytes of the
patient with RP11-120I18 in 14q12 and wcp 14 probes.
The rearrangement was molecular cytogenetically unbal-
anced (data not shown), therefore the karyotype is: 46,XX,
del[12](q12q12).ish14q12(RP11-120I18-). arr[hg19]14q12
(25,843,560-29,938,629)x1. Blood samples from both par-
ents were examined with FISH in order to exclude any
chromosome rearrangement like inversion. Ten meta-
phases were analysed from each subject with RP11-332 N6
in 14q11.2, RP11-120I18 in 14q12 and wcp 14 probes, and
no rearrangement was detected (data not shown).
Discussion
Recently, the FOXG1 congenital variant of Rett syndrome
has been described as a clinically identifiable phenotype,
called the “FOXG1 syndrome” [13]. This is an epileptic-
dyskinetic developmental encephalopathy with features of
classic Rett syndrome, but earlier onset from the first
months of life. The main phenotype comprises postnatal
microcephaly, severe developmental delay and lack of
speech, hypotonia, dyskinesia and corpus callosum hypo-
plasia. Other symptoms include strabismus, feeding diffi-
culties, bruxism and seizures [8, 12–16].
In the present study, a novel FOXG1 and a NOVA1
deletion is described. According to the diagnostic criteria
for typical and atypical Rett syndrome [7], our patient
possesses only some of the diagnostic criteria for the
atypical Rett syndrome. She has slight facial dysmorph-
ism, feeding difficulties, severe psychomotor retardation,
postnatal microcephaly, seizures and focal cerebral
dysfunction, strabismus and hypertonia. A deletion of
4.09 Mb on chromosome 14q12 including the FOXG1
and NOVA1 genes was identified by array-CGH tech-
nique. The clinical phenotypes vary between the re-
ported cases that have mutations or deletions involving
the FOXG1 gene and other genes (Table 1, Fig. 3). Our
case differs as only two genes, FOXG1 and NOVA1, are
involved. These genes were found to be highly expressed
in the human brain throughout ontogeny, and double
strand breaks in 14q12 region are implicated in the neu-
rodegenerative disease: ataxia telangiectasia [17].
Different clinical features have also been described in
patients with FOXG1 point mutations. The severity or
lack of the symptoms among cases could depend
Fig. 3 Ideogram of the deletions described in Table 1. The upper thin line indicates the 14q12 region (hg38), and the bold lines indicate the
region which is deleted in each case. Cellini et al. 2015 case 3 has a deletion beyond 14q12 and is drawn with a discontinued line
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additionally on genetic and/or environmental factors
[13]. Jacob F. et al. in 2009 [9] reported a case of a
2.594 Mb deletion involving the FOXG1 and C23orf14
(Table 1). As in our case, patient had a normal cor-
pus callosum but showed all the typical characteristics
found in patients with FOXG1 alterations. Table 1 in-
dicates that almost all cases suffer from microcephaly,
dyskinesia, lack of speech, seizures and developmental
delay. On the other hand, hypotonia and corpus callo-
sum hypoplasia are not apparent in every case. Pro-
gressive hypertonia was obvious in our patient and in
at least 10 other reported cases with FOXG1 point
mutations [8].
Forkhead BOX G1 (FOXG1) gene (OMIM*164874)
encodes a developmental transcription factor with re-
pressor activity, important for the development of the
ventral telencephalon in the embryonic forebrain and
crucial for the regulation of neurogenesis and neurite
outgrowth. It is also expressed in neurogenetic regions
of the postnatal brain [15]. Postnatal microcephaly is
another common feature of FOXG1 syndrome. In
cases with a duplication of the FOXG1 gene, micro-
cephaly is not found (Table 1), indicating that the
phenotype is dependent on FOXG1 dosage. Further-
more, other reported cases with deletions close but not
disturbing the FOXG1 gene have a similar phenotype
as patients with ¨FOXG1 syndrome¨, suggesting that a
position effect causing altered expression of FOXG1 gene
may be the cause. The protein Kinase D1 (PRKD1) gene
(OMIM*605435), located close to FOXG1 gene has been
reported to be implicated in transcription and expression
of FOXG1 gene [14].
Neuro-Oncological Ventral Antigen 1 (NOVA1) gene
(OMIM*602157) encodes a neuron-specific RNA-
binding protein that is inhibited by paraneoplastic anti-
bodies [18]. Recently, Storchel H et al., 2015 [19] found
that NOVA1 protein converges on Ago proteins and
controls miRNA-induced silencing complex (miRISC),
possibly resulting on the regulation of neuronal develop-
ment and synaptic plasticity. Despite the significant role
of the NOVA1 gene, it has not been linked to any human
phenotype yet. In the case of our patient with FOXG1
syndrome, we are unable to estimate the impact of the
NOVA1 haploinsufficiency. NOVA1 haploinsufficiency
may act synergistically with the FOXG1 gene or it
may cause no difference in the final clinical outcome.
Also, we cannot define whether the IVF by ICSI plays
a role in the microdeletion of chromosome 14q12 re-
gion. Further research should investigate if ICSI could
be associated with haploinsufficiency as was the case
in our patient.
In conclusion, we present a female patient with clin-
ical features compatible with the congenital variant of
Rett syndrome.
Conclusion
Since our patient is the only one with a deletion encom-
passing only FOXG1 and NOVA1 genes, in the future
the thorough clinical follow-up of her neurological sta-
tus will help for further delineation of the role of these
genes.
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